Global Tumor Immunotherapy Drugs Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Tumor immunotherapy refers to destroying cancer cells by stimulating and activating the patient's own immune system.
The global Tumor Immunotherapy Drugs market size is projected to grow from US$ 41670 million in 2023 to US$ 77330 million in 2030; it is expected to grow at a CAGR of 9.2% from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Tumor Immunotherapy Drugs Industry Forecast” looks at past sales and reviews total world Tumor Immunotherapy Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Tumor Immunotherapy Drugs sales for 2024 through 2030. With Tumor Immunotherapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Immunotherapy Drugs industry.
This Insight Report provides a comprehensive analysis of the global Tumor Immunotherapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Immunotherapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Immunotherapy Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Immunotherapy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Immunotherapy Drugs.
United States market for Tumor Immunotherapy Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Tumor Immunotherapy Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Tumor Immunotherapy Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Tumor Immunotherapy Drugs players cover Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech and Ono Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Immunotherapy Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
What is the 10-year outlook for the global Tumor Immunotherapy Drugs market?
What factors are driving Tumor Immunotherapy Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Tumor Immunotherapy Drugs market opportunities vary by end market size?
How does Tumor Immunotherapy Drugs break out type, application?
Tumor immunotherapy refers to destroying cancer cells by stimulating and activating the patient's own immune system.
The global Tumor Immunotherapy Drugs market size is projected to grow from US$ 41670 million in 2023 to US$ 77330 million in 2030; it is expected to grow at a CAGR of 9.2% from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Tumor Immunotherapy Drugs Industry Forecast” looks at past sales and reviews total world Tumor Immunotherapy Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Tumor Immunotherapy Drugs sales for 2024 through 2030. With Tumor Immunotherapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Immunotherapy Drugs industry.
This Insight Report provides a comprehensive analysis of the global Tumor Immunotherapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Immunotherapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Immunotherapy Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Immunotherapy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Immunotherapy Drugs.
United States market for Tumor Immunotherapy Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Tumor Immunotherapy Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Tumor Immunotherapy Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Tumor Immunotherapy Drugs players cover Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech and Ono Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Immunotherapy Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
- Immune Checkpoint Inhibitors
- Tumor Vaccine
- Adoptive Immunotherapy
- Non-specific Immunomodulator
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bristol Myer Squibb
- AstraZeneca
- Merck
- Roche / Genentech
- Ono Pharmaceutical
- Regeneron
- Innovent
- Hengrui Medicine
- Junshi Biosciences
- Pfizer, Inc
- F. Hoffmann-La Roche Ltd
- Incyte Corporation
- NewLink Genetics Corporation
- Celldex Therapeutics, Inc
- GlaxoSmithKline
What is the 10-year outlook for the global Tumor Immunotherapy Drugs market?
What factors are driving Tumor Immunotherapy Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Tumor Immunotherapy Drugs market opportunities vary by end market size?
How does Tumor Immunotherapy Drugs break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Tumor Immunotherapy Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Tumor Immunotherapy Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Tumor Immunotherapy Drugs by Country/Region, 2019, 2023 & 2030
2.2 Tumor Immunotherapy Drugs Segment by Type
2.2.1 Immune Checkpoint Inhibitors
2.2.2 Tumor Vaccine
2.2.3 Adoptive Immunotherapy
2.2.4 Non-specific Immunomodulator
2.3 Tumor Immunotherapy Drugs Sales by Type
2.3.1 Global Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Tumor Immunotherapy Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Tumor Immunotherapy Drugs Sale Price by Type (2019-2024)
2.4 Tumor Immunotherapy Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Tumor Immunotherapy Drugs Sales by Application
2.5.1 Global Tumor Immunotherapy Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Tumor Immunotherapy Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Tumor Immunotherapy Drugs Sale Price by Application (2019-2024)
3 GLOBAL TUMOR IMMUNOTHERAPY DRUGS BY COMPANY
3.1 Global Tumor Immunotherapy Drugs Breakdown Data by Company
3.1.1 Global Tumor Immunotherapy Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Tumor Immunotherapy Drugs Sales Market Share by Company (2019-2024)
3.2 Global Tumor Immunotherapy Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Tumor Immunotherapy Drugs Revenue by Company (2019-2024)
3.2.2 Global Tumor Immunotherapy Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Tumor Immunotherapy Drugs Sale Price by Company
3.4 Key Manufacturers Tumor Immunotherapy Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tumor Immunotherapy Drugs Product Location Distribution
3.4.2 Players Tumor Immunotherapy Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR TUMOR IMMUNOTHERAPY DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Tumor Immunotherapy Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Tumor Immunotherapy Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Tumor Immunotherapy Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Tumor Immunotherapy Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Tumor Immunotherapy Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Tumor Immunotherapy Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Tumor Immunotherapy Drugs Sales Growth
4.4 APAC Tumor Immunotherapy Drugs Sales Growth
4.5 Europe Tumor Immunotherapy Drugs Sales Growth
4.6 Middle East & Africa Tumor Immunotherapy Drugs Sales Growth
5 AMERICAS
5.1 Americas Tumor Immunotherapy Drugs Sales by Country
5.1.1 Americas Tumor Immunotherapy Drugs Sales by Country (2019-2024)
5.1.2 Americas Tumor Immunotherapy Drugs Revenue by Country (2019-2024)
5.2 Americas Tumor Immunotherapy Drugs Sales by Type
5.3 Americas Tumor Immunotherapy Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Immunotherapy Drugs Sales by Region
6.1.1 APAC Tumor Immunotherapy Drugs Sales by Region (2019-2024)
6.1.2 APAC Tumor Immunotherapy Drugs Revenue by Region (2019-2024)
6.2 APAC Tumor Immunotherapy Drugs Sales by Type
6.3 APAC Tumor Immunotherapy Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Tumor Immunotherapy Drugs by Country
7.1.1 Europe Tumor Immunotherapy Drugs Sales by Country (2019-2024)
7.1.2 Europe Tumor Immunotherapy Drugs Revenue by Country (2019-2024)
7.2 Europe Tumor Immunotherapy Drugs Sales by Type
7.3 Europe Tumor Immunotherapy Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Tumor Immunotherapy Drugs by Country
8.1.1 Middle East & Africa Tumor Immunotherapy Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Tumor Immunotherapy Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Tumor Immunotherapy Drugs Sales by Type
8.3 Middle East & Africa Tumor Immunotherapy Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tumor Immunotherapy Drugs
10.3 Manufacturing Process Analysis of Tumor Immunotherapy Drugs
10.4 Industry Chain Structure of Tumor Immunotherapy Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tumor Immunotherapy Drugs Distributors
11.3 Tumor Immunotherapy Drugs Customer
12 WORLD FORECAST REVIEW FOR TUMOR IMMUNOTHERAPY DRUGS BY GEOGRAPHIC REGION
12.1 Global Tumor Immunotherapy Drugs Market Size Forecast by Region
12.1.1 Global Tumor Immunotherapy Drugs Forecast by Region (2025-2030)
12.1.2 Global Tumor Immunotherapy Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Tumor Immunotherapy Drugs Forecast by Type
12.7 Global Tumor Immunotherapy Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Bristol Myer Squibb
13.1.1 Bristol Myer Squibb Company Information
13.1.2 Bristol Myer Squibb Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.1.3 Bristol Myer Squibb Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bristol Myer Squibb Main Business Overview
13.1.5 Bristol Myer Squibb Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.2.3 AstraZeneca Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.3.3 Merck Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Roche / Genentech
13.4.1 Roche / Genentech Company Information
13.4.2 Roche / Genentech Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.4.3 Roche / Genentech Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Roche / Genentech Main Business Overview
13.4.5 Roche / Genentech Latest Developments
13.5 Ono Pharmaceutical
13.5.1 Ono Pharmaceutical Company Information
13.5.2 Ono Pharmaceutical Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.5.3 Ono Pharmaceutical Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Ono Pharmaceutical Main Business Overview
13.5.5 Ono Pharmaceutical Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.6.3 Regeneron Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Innovent
13.7.1 Innovent Company Information
13.7.2 Innovent Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.7.3 Innovent Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Innovent Main Business Overview
13.7.5 Innovent Latest Developments
13.8 Hengrui Medicine
13.8.1 Hengrui Medicine Company Information
13.8.2 Hengrui Medicine Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.8.3 Hengrui Medicine Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Hengrui Medicine Main Business Overview
13.8.5 Hengrui Medicine Latest Developments
13.9 Junshi Biosciences
13.9.1 Junshi Biosciences Company Information
13.9.2 Junshi Biosciences Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.9.3 Junshi Biosciences Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Junshi Biosciences Main Business Overview
13.9.5 Junshi Biosciences Latest Developments
13.10 Pfizer, Inc
13.10.1 Pfizer, Inc Company Information
13.10.2 Pfizer, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.10.3 Pfizer, Inc Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Pfizer, Inc Main Business Overview
13.10.5 Pfizer, Inc Latest Developments
13.11 F. Hoffmann-La Roche Ltd
13.11.1 F. Hoffmann-La Roche Ltd Company Information
13.11.2 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.11.3 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.11.5 F. Hoffmann-La Roche Ltd Latest Developments
13.12 Incyte Corporation
13.12.1 Incyte Corporation Company Information
13.12.2 Incyte Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.12.3 Incyte Corporation Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Incyte Corporation Main Business Overview
13.12.5 Incyte Corporation Latest Developments
13.13 NewLink Genetics Corporation
13.13.1 NewLink Genetics Corporation Company Information
13.13.2 NewLink Genetics Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.13.3 NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 NewLink Genetics Corporation Main Business Overview
13.13.5 NewLink Genetics Corporation Latest Developments
13.14 Celldex Therapeutics, Inc
13.14.1 Celldex Therapeutics, Inc Company Information
13.14.2 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.14.3 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Celldex Therapeutics, Inc Main Business Overview
13.14.5 Celldex Therapeutics, Inc Latest Developments
13.15 GlaxoSmithKline
13.15.1 GlaxoSmithKline Company Information
13.15.2 GlaxoSmithKline Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.15.3 GlaxoSmithKline Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 GlaxoSmithKline Main Business Overview
13.15.5 GlaxoSmithKline Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Tumor Immunotherapy Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Tumor Immunotherapy Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Tumor Immunotherapy Drugs by Country/Region, 2019, 2023 & 2030
2.2 Tumor Immunotherapy Drugs Segment by Type
2.2.1 Immune Checkpoint Inhibitors
2.2.2 Tumor Vaccine
2.2.3 Adoptive Immunotherapy
2.2.4 Non-specific Immunomodulator
2.3 Tumor Immunotherapy Drugs Sales by Type
2.3.1 Global Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Tumor Immunotherapy Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Tumor Immunotherapy Drugs Sale Price by Type (2019-2024)
2.4 Tumor Immunotherapy Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Tumor Immunotherapy Drugs Sales by Application
2.5.1 Global Tumor Immunotherapy Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Tumor Immunotherapy Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Tumor Immunotherapy Drugs Sale Price by Application (2019-2024)
3 GLOBAL TUMOR IMMUNOTHERAPY DRUGS BY COMPANY
3.1 Global Tumor Immunotherapy Drugs Breakdown Data by Company
3.1.1 Global Tumor Immunotherapy Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Tumor Immunotherapy Drugs Sales Market Share by Company (2019-2024)
3.2 Global Tumor Immunotherapy Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Tumor Immunotherapy Drugs Revenue by Company (2019-2024)
3.2.2 Global Tumor Immunotherapy Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Tumor Immunotherapy Drugs Sale Price by Company
3.4 Key Manufacturers Tumor Immunotherapy Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tumor Immunotherapy Drugs Product Location Distribution
3.4.2 Players Tumor Immunotherapy Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR TUMOR IMMUNOTHERAPY DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Tumor Immunotherapy Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Tumor Immunotherapy Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Tumor Immunotherapy Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Tumor Immunotherapy Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Tumor Immunotherapy Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Tumor Immunotherapy Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Tumor Immunotherapy Drugs Sales Growth
4.4 APAC Tumor Immunotherapy Drugs Sales Growth
4.5 Europe Tumor Immunotherapy Drugs Sales Growth
4.6 Middle East & Africa Tumor Immunotherapy Drugs Sales Growth
5 AMERICAS
5.1 Americas Tumor Immunotherapy Drugs Sales by Country
5.1.1 Americas Tumor Immunotherapy Drugs Sales by Country (2019-2024)
5.1.2 Americas Tumor Immunotherapy Drugs Revenue by Country (2019-2024)
5.2 Americas Tumor Immunotherapy Drugs Sales by Type
5.3 Americas Tumor Immunotherapy Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Immunotherapy Drugs Sales by Region
6.1.1 APAC Tumor Immunotherapy Drugs Sales by Region (2019-2024)
6.1.2 APAC Tumor Immunotherapy Drugs Revenue by Region (2019-2024)
6.2 APAC Tumor Immunotherapy Drugs Sales by Type
6.3 APAC Tumor Immunotherapy Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Tumor Immunotherapy Drugs by Country
7.1.1 Europe Tumor Immunotherapy Drugs Sales by Country (2019-2024)
7.1.2 Europe Tumor Immunotherapy Drugs Revenue by Country (2019-2024)
7.2 Europe Tumor Immunotherapy Drugs Sales by Type
7.3 Europe Tumor Immunotherapy Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Tumor Immunotherapy Drugs by Country
8.1.1 Middle East & Africa Tumor Immunotherapy Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Tumor Immunotherapy Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Tumor Immunotherapy Drugs Sales by Type
8.3 Middle East & Africa Tumor Immunotherapy Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tumor Immunotherapy Drugs
10.3 Manufacturing Process Analysis of Tumor Immunotherapy Drugs
10.4 Industry Chain Structure of Tumor Immunotherapy Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tumor Immunotherapy Drugs Distributors
11.3 Tumor Immunotherapy Drugs Customer
12 WORLD FORECAST REVIEW FOR TUMOR IMMUNOTHERAPY DRUGS BY GEOGRAPHIC REGION
12.1 Global Tumor Immunotherapy Drugs Market Size Forecast by Region
12.1.1 Global Tumor Immunotherapy Drugs Forecast by Region (2025-2030)
12.1.2 Global Tumor Immunotherapy Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Tumor Immunotherapy Drugs Forecast by Type
12.7 Global Tumor Immunotherapy Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Bristol Myer Squibb
13.1.1 Bristol Myer Squibb Company Information
13.1.2 Bristol Myer Squibb Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.1.3 Bristol Myer Squibb Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bristol Myer Squibb Main Business Overview
13.1.5 Bristol Myer Squibb Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.2.3 AstraZeneca Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.3.3 Merck Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Roche / Genentech
13.4.1 Roche / Genentech Company Information
13.4.2 Roche / Genentech Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.4.3 Roche / Genentech Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Roche / Genentech Main Business Overview
13.4.5 Roche / Genentech Latest Developments
13.5 Ono Pharmaceutical
13.5.1 Ono Pharmaceutical Company Information
13.5.2 Ono Pharmaceutical Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.5.3 Ono Pharmaceutical Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Ono Pharmaceutical Main Business Overview
13.5.5 Ono Pharmaceutical Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.6.3 Regeneron Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Innovent
13.7.1 Innovent Company Information
13.7.2 Innovent Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.7.3 Innovent Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Innovent Main Business Overview
13.7.5 Innovent Latest Developments
13.8 Hengrui Medicine
13.8.1 Hengrui Medicine Company Information
13.8.2 Hengrui Medicine Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.8.3 Hengrui Medicine Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Hengrui Medicine Main Business Overview
13.8.5 Hengrui Medicine Latest Developments
13.9 Junshi Biosciences
13.9.1 Junshi Biosciences Company Information
13.9.2 Junshi Biosciences Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.9.3 Junshi Biosciences Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Junshi Biosciences Main Business Overview
13.9.5 Junshi Biosciences Latest Developments
13.10 Pfizer, Inc
13.10.1 Pfizer, Inc Company Information
13.10.2 Pfizer, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.10.3 Pfizer, Inc Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Pfizer, Inc Main Business Overview
13.10.5 Pfizer, Inc Latest Developments
13.11 F. Hoffmann-La Roche Ltd
13.11.1 F. Hoffmann-La Roche Ltd Company Information
13.11.2 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.11.3 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.11.5 F. Hoffmann-La Roche Ltd Latest Developments
13.12 Incyte Corporation
13.12.1 Incyte Corporation Company Information
13.12.2 Incyte Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.12.3 Incyte Corporation Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Incyte Corporation Main Business Overview
13.12.5 Incyte Corporation Latest Developments
13.13 NewLink Genetics Corporation
13.13.1 NewLink Genetics Corporation Company Information
13.13.2 NewLink Genetics Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.13.3 NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 NewLink Genetics Corporation Main Business Overview
13.13.5 NewLink Genetics Corporation Latest Developments
13.14 Celldex Therapeutics, Inc
13.14.1 Celldex Therapeutics, Inc Company Information
13.14.2 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.14.3 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Celldex Therapeutics, Inc Main Business Overview
13.14.5 Celldex Therapeutics, Inc Latest Developments
13.15 GlaxoSmithKline
13.15.1 GlaxoSmithKline Company Information
13.15.2 GlaxoSmithKline Tumor Immunotherapy Drugs Product Portfolios and Specifications
13.15.3 GlaxoSmithKline Tumor Immunotherapy Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 GlaxoSmithKline Main Business Overview
13.15.5 GlaxoSmithKline Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Tumor Immunotherapy Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Tumor Immunotherapy Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Immune Checkpoint Inhibitors
Table 4. Major Players of Tumor Vaccine
Table 5. Major Players of Adoptive Immunotherapy
Table 6. Major Players of Non-specific Immunomodulator
Table 7. Global Tumor Immunotherapy Drugs Sales by Type (2019-2024) & (K Units)
Table 8. Global Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
Table 9. Global Tumor Immunotherapy Drugs Revenue by Type (2019-2024) & ($ million)
Table 10. Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2019-2024)
Table 11. Global Tumor Immunotherapy Drugs Sale Price by Type (2019-2024) & (US$/Unit)
Table 12. Global Tumor Immunotherapy Drugs Sales by Application (2019-2024) & (K Units)
Table 13. Global Tumor Immunotherapy Drugs Sales Market Share by Application (2019-2024)
Table 14. Global Tumor Immunotherapy Drugs Revenue by Application (2019-2024)
Table 15. Global Tumor Immunotherapy Drugs Revenue Market Share by Application (2019-2024)
Table 16. Global Tumor Immunotherapy Drugs Sale Price by Application (2019-2024) & (US$/Unit)
Table 17. Global Tumor Immunotherapy Drugs Sales by Company (2019-2024) & (K Units)
Table 18. Global Tumor Immunotherapy Drugs Sales Market Share by Company (2019-2024)
Table 19. Global Tumor Immunotherapy Drugs Revenue by Company (2019-2024) ($ Millions)
Table 20. Global Tumor Immunotherapy Drugs Revenue Market Share by Company (2019-2024)
Table 21. Global Tumor Immunotherapy Drugs Sale Price by Company (2019-2024) & (US$/Unit)
Table 22. Key Manufacturers Tumor Immunotherapy Drugs Producing Area Distribution and Sales Area
Table 23. Players Tumor Immunotherapy Drugs Products Offered
Table 24. Tumor Immunotherapy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Tumor Immunotherapy Drugs Sales by Geographic Region (2019-2024) & (K Units)
Table 28. Global Tumor Immunotherapy Drugs Sales Market Share Geographic Region (2019-2024)
Table 29. Global Tumor Immunotherapy Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Tumor Immunotherapy Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Tumor Immunotherapy Drugs Sales by Country/Region (2019-2024) & (K Units)
Table 32. Global Tumor Immunotherapy Drugs Sales Market Share by Country/Region (2019-2024)
Table 33. Global Tumor Immunotherapy Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Tumor Immunotherapy Drugs Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Tumor Immunotherapy Drugs Sales by Country (2019-2024) & (K Units)
Table 36. Americas Tumor Immunotherapy Drugs Sales Market Share by Country (2019-2024)
Table 37. Americas Tumor Immunotherapy Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas Tumor Immunotherapy Drugs Revenue Market Share by Country (2019-2024)
Table 39. Americas Tumor Immunotherapy Drugs Sales by Type (2019-2024) & (K Units)
Table 40. Americas Tumor Immunotherapy Drugs Sales by Application (2019-2024) & (K Units)
Table 41. APAC Tumor Immunotherapy Drugs Sales by Region (2019-2024) & (K Units)
Table 42. APAC Tumor Immunotherapy Drugs Sales Market Share by Region (2019-2024)
Table 43. APAC Tumor Immunotherapy Drugs Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC Tumor Immunotherapy Drugs Revenue Market Share by Region (2019-2024)
Table 45. APAC Tumor Immunotherapy Drugs Sales by Type (2019-2024) & (K Units)
Table 46. APAC Tumor Immunotherapy Drugs Sales by Application (2019-2024) & (K Units)
Table 47. Europe Tumor Immunotherapy Drugs Sales by Country (2019-2024) & (K Units)
Table 48. Europe Tumor Immunotherapy Drugs Sales Market Share by Country (2019-2024)
Table 49. Europe Tumor Immunotherapy Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe Tumor Immunotherapy Drugs Revenue Market Share by Country (2019-2024)
Table 51. Europe Tumor Immunotherapy Drugs Sales by Type (2019-2024) & (K Units)
Table 52. Europe Tumor Immunotherapy Drugs Sales by Application (2019-2024) & (K Units)
Table 53. Middle East & Africa Tumor Immunotherapy Drugs Sales by Country (2019-2024) & (K Units)
Table 54. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa Tumor Immunotherapy Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa Tumor Immunotherapy Drugs Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa Tumor Immunotherapy Drugs Sales by Type (2019-2024) & (K Units)
Table 58. Middle East & Africa Tumor Immunotherapy Drugs Sales by Application (2019-2024) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Tumor Immunotherapy Drugs
Table 60. Key Market Challenges & Risks of Tumor Immunotherapy Drugs
Table 61. Key Industry Trends of Tumor Immunotherapy Drugs
Table 62. Tumor Immunotherapy Drugs Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Tumor Immunotherapy Drugs Distributors List
Table 65. Tumor Immunotherapy Drugs Customer List
Table 66. Global Tumor Immunotherapy Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 67. Global Tumor Immunotherapy Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas Tumor Immunotherapy Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 69. Americas Tumor Immunotherapy Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC Tumor Immunotherapy Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 71. APAC Tumor Immunotherapy Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe Tumor Immunotherapy Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Europe Tumor Immunotherapy Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa Tumor Immunotherapy Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 75. Middle East & Africa Tumor Immunotherapy Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global Tumor Immunotherapy Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 77. Global Tumor Immunotherapy Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global Tumor Immunotherapy Drugs Sales Forecast by Application (2025-2030) & (K Units)
Table 79. Global Tumor Immunotherapy Drugs Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 80. Bristol Myer Squibb Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 81. Bristol Myer Squibb Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 82. Bristol Myer Squibb Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Bristol Myer Squibb Main Business
Table 84. Bristol Myer Squibb Latest Developments
Table 85. AstraZeneca Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 86. AstraZeneca Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 87. AstraZeneca Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. AstraZeneca Main Business
Table 89. AstraZeneca Latest Developments
Table 90. Merck Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Merck Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 92. Merck Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Merck Main Business
Table 94. Merck Latest Developments
Table 95. Roche / Genentech Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Roche / Genentech Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 97. Roche / Genentech Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Roche / Genentech Main Business
Table 99. Roche / Genentech Latest Developments
Table 100. Ono Pharmaceutical Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. Ono Pharmaceutical Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 102. Ono Pharmaceutical Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Ono Pharmaceutical Main Business
Table 104. Ono Pharmaceutical Latest Developments
Table 105. Regeneron Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Regeneron Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 107. Regeneron Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Regeneron Main Business
Table 109. Regeneron Latest Developments
Table 110. Innovent Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 111. Innovent Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 112. Innovent Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Innovent Main Business
Table 114. Innovent Latest Developments
Table 115. Hengrui Medicine Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 116. Hengrui Medicine Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 117. Hengrui Medicine Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Hengrui Medicine Main Business
Table 119. Hengrui Medicine Latest Developments
Table 120. Junshi Biosciences Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 121. Junshi Biosciences Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 122. Junshi Biosciences Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Junshi Biosciences Main Business
Table 124. Junshi Biosciences Latest Developments
Table 125. Pfizer, Inc Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 126. Pfizer, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 127. Pfizer, Inc Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Pfizer, Inc Main Business
Table 129. Pfizer, Inc Latest Developments
Table 130. F. Hoffmann-La Roche Ltd Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 131. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 132. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. F. Hoffmann-La Roche Ltd Main Business
Table 134. F. Hoffmann-La Roche Ltd Latest Developments
Table 135. Incyte Corporation Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 136. Incyte Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 137. Incyte Corporation Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Incyte Corporation Main Business
Table 139. Incyte Corporation Latest Developments
Table 140. NewLink Genetics Corporation Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 141. NewLink Genetics Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 142. NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. NewLink Genetics Corporation Main Business
Table 144. NewLink Genetics Corporation Latest Developments
Table 145. Celldex Therapeutics, Inc Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 146. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 147. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Celldex Therapeutics, Inc Main Business
Table 149. Celldex Therapeutics, Inc Latest Developments
Table 150. GlaxoSmithKline Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 151. GlaxoSmithKline Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 152. GlaxoSmithKline Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. GlaxoSmithKline Main Business
Table 154. GlaxoSmithKline Latest Developments
Table 1. Tumor Immunotherapy Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Tumor Immunotherapy Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Immune Checkpoint Inhibitors
Table 4. Major Players of Tumor Vaccine
Table 5. Major Players of Adoptive Immunotherapy
Table 6. Major Players of Non-specific Immunomodulator
Table 7. Global Tumor Immunotherapy Drugs Sales by Type (2019-2024) & (K Units)
Table 8. Global Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
Table 9. Global Tumor Immunotherapy Drugs Revenue by Type (2019-2024) & ($ million)
Table 10. Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2019-2024)
Table 11. Global Tumor Immunotherapy Drugs Sale Price by Type (2019-2024) & (US$/Unit)
Table 12. Global Tumor Immunotherapy Drugs Sales by Application (2019-2024) & (K Units)
Table 13. Global Tumor Immunotherapy Drugs Sales Market Share by Application (2019-2024)
Table 14. Global Tumor Immunotherapy Drugs Revenue by Application (2019-2024)
Table 15. Global Tumor Immunotherapy Drugs Revenue Market Share by Application (2019-2024)
Table 16. Global Tumor Immunotherapy Drugs Sale Price by Application (2019-2024) & (US$/Unit)
Table 17. Global Tumor Immunotherapy Drugs Sales by Company (2019-2024) & (K Units)
Table 18. Global Tumor Immunotherapy Drugs Sales Market Share by Company (2019-2024)
Table 19. Global Tumor Immunotherapy Drugs Revenue by Company (2019-2024) ($ Millions)
Table 20. Global Tumor Immunotherapy Drugs Revenue Market Share by Company (2019-2024)
Table 21. Global Tumor Immunotherapy Drugs Sale Price by Company (2019-2024) & (US$/Unit)
Table 22. Key Manufacturers Tumor Immunotherapy Drugs Producing Area Distribution and Sales Area
Table 23. Players Tumor Immunotherapy Drugs Products Offered
Table 24. Tumor Immunotherapy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Tumor Immunotherapy Drugs Sales by Geographic Region (2019-2024) & (K Units)
Table 28. Global Tumor Immunotherapy Drugs Sales Market Share Geographic Region (2019-2024)
Table 29. Global Tumor Immunotherapy Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Tumor Immunotherapy Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Tumor Immunotherapy Drugs Sales by Country/Region (2019-2024) & (K Units)
Table 32. Global Tumor Immunotherapy Drugs Sales Market Share by Country/Region (2019-2024)
Table 33. Global Tumor Immunotherapy Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Tumor Immunotherapy Drugs Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Tumor Immunotherapy Drugs Sales by Country (2019-2024) & (K Units)
Table 36. Americas Tumor Immunotherapy Drugs Sales Market Share by Country (2019-2024)
Table 37. Americas Tumor Immunotherapy Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas Tumor Immunotherapy Drugs Revenue Market Share by Country (2019-2024)
Table 39. Americas Tumor Immunotherapy Drugs Sales by Type (2019-2024) & (K Units)
Table 40. Americas Tumor Immunotherapy Drugs Sales by Application (2019-2024) & (K Units)
Table 41. APAC Tumor Immunotherapy Drugs Sales by Region (2019-2024) & (K Units)
Table 42. APAC Tumor Immunotherapy Drugs Sales Market Share by Region (2019-2024)
Table 43. APAC Tumor Immunotherapy Drugs Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC Tumor Immunotherapy Drugs Revenue Market Share by Region (2019-2024)
Table 45. APAC Tumor Immunotherapy Drugs Sales by Type (2019-2024) & (K Units)
Table 46. APAC Tumor Immunotherapy Drugs Sales by Application (2019-2024) & (K Units)
Table 47. Europe Tumor Immunotherapy Drugs Sales by Country (2019-2024) & (K Units)
Table 48. Europe Tumor Immunotherapy Drugs Sales Market Share by Country (2019-2024)
Table 49. Europe Tumor Immunotherapy Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe Tumor Immunotherapy Drugs Revenue Market Share by Country (2019-2024)
Table 51. Europe Tumor Immunotherapy Drugs Sales by Type (2019-2024) & (K Units)
Table 52. Europe Tumor Immunotherapy Drugs Sales by Application (2019-2024) & (K Units)
Table 53. Middle East & Africa Tumor Immunotherapy Drugs Sales by Country (2019-2024) & (K Units)
Table 54. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa Tumor Immunotherapy Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa Tumor Immunotherapy Drugs Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa Tumor Immunotherapy Drugs Sales by Type (2019-2024) & (K Units)
Table 58. Middle East & Africa Tumor Immunotherapy Drugs Sales by Application (2019-2024) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Tumor Immunotherapy Drugs
Table 60. Key Market Challenges & Risks of Tumor Immunotherapy Drugs
Table 61. Key Industry Trends of Tumor Immunotherapy Drugs
Table 62. Tumor Immunotherapy Drugs Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Tumor Immunotherapy Drugs Distributors List
Table 65. Tumor Immunotherapy Drugs Customer List
Table 66. Global Tumor Immunotherapy Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 67. Global Tumor Immunotherapy Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas Tumor Immunotherapy Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 69. Americas Tumor Immunotherapy Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC Tumor Immunotherapy Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 71. APAC Tumor Immunotherapy Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe Tumor Immunotherapy Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Europe Tumor Immunotherapy Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa Tumor Immunotherapy Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 75. Middle East & Africa Tumor Immunotherapy Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global Tumor Immunotherapy Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 77. Global Tumor Immunotherapy Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global Tumor Immunotherapy Drugs Sales Forecast by Application (2025-2030) & (K Units)
Table 79. Global Tumor Immunotherapy Drugs Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 80. Bristol Myer Squibb Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 81. Bristol Myer Squibb Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 82. Bristol Myer Squibb Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Bristol Myer Squibb Main Business
Table 84. Bristol Myer Squibb Latest Developments
Table 85. AstraZeneca Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 86. AstraZeneca Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 87. AstraZeneca Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. AstraZeneca Main Business
Table 89. AstraZeneca Latest Developments
Table 90. Merck Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Merck Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 92. Merck Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Merck Main Business
Table 94. Merck Latest Developments
Table 95. Roche / Genentech Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Roche / Genentech Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 97. Roche / Genentech Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Roche / Genentech Main Business
Table 99. Roche / Genentech Latest Developments
Table 100. Ono Pharmaceutical Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. Ono Pharmaceutical Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 102. Ono Pharmaceutical Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Ono Pharmaceutical Main Business
Table 104. Ono Pharmaceutical Latest Developments
Table 105. Regeneron Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Regeneron Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 107. Regeneron Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Regeneron Main Business
Table 109. Regeneron Latest Developments
Table 110. Innovent Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 111. Innovent Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 112. Innovent Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Innovent Main Business
Table 114. Innovent Latest Developments
Table 115. Hengrui Medicine Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 116. Hengrui Medicine Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 117. Hengrui Medicine Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Hengrui Medicine Main Business
Table 119. Hengrui Medicine Latest Developments
Table 120. Junshi Biosciences Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 121. Junshi Biosciences Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 122. Junshi Biosciences Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Junshi Biosciences Main Business
Table 124. Junshi Biosciences Latest Developments
Table 125. Pfizer, Inc Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 126. Pfizer, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 127. Pfizer, Inc Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Pfizer, Inc Main Business
Table 129. Pfizer, Inc Latest Developments
Table 130. F. Hoffmann-La Roche Ltd Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 131. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 132. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. F. Hoffmann-La Roche Ltd Main Business
Table 134. F. Hoffmann-La Roche Ltd Latest Developments
Table 135. Incyte Corporation Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 136. Incyte Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 137. Incyte Corporation Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Incyte Corporation Main Business
Table 139. Incyte Corporation Latest Developments
Table 140. NewLink Genetics Corporation Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 141. NewLink Genetics Corporation Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 142. NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. NewLink Genetics Corporation Main Business
Table 144. NewLink Genetics Corporation Latest Developments
Table 145. Celldex Therapeutics, Inc Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 146. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 147. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Celldex Therapeutics, Inc Main Business
Table 149. Celldex Therapeutics, Inc Latest Developments
Table 150. GlaxoSmithKline Basic Information, Tumor Immunotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 151. GlaxoSmithKline Tumor Immunotherapy Drugs Product Portfolios and Specifications
Table 152. GlaxoSmithKline Tumor Immunotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. GlaxoSmithKline Main Business
Table 154. GlaxoSmithKline Latest Developments
LIST OF FIGURES
Figure 1. Picture of Tumor Immunotherapy Drugs
Figure 2. Tumor Immunotherapy Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Tumor Immunotherapy Drugs Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Tumor Immunotherapy Drugs Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Tumor Immunotherapy Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Immune Checkpoint Inhibitors
Figure 10. Product Picture of Tumor Vaccine
Figure 11. Product Picture of Adoptive Immunotherapy
Figure 12. Product Picture of Non-specific Immunomodulator
Figure 13. Global Tumor Immunotherapy Drugs Sales Market Share by Type in 2023
Figure 14. Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2019-2024)
Figure 15. Tumor Immunotherapy Drugs Consumed in Hospital
Figure 16. Global Tumor Immunotherapy Drugs Market: Hospital (2019-2024) & (K Units)
Figure 17. Tumor Immunotherapy Drugs Consumed in Clinic
Figure 18. Global Tumor Immunotherapy Drugs Market: Clinic (2019-2024) & (K Units)
Figure 19. Tumor Immunotherapy Drugs Consumed in Other
Figure 20. Global Tumor Immunotherapy Drugs Market: Other (2019-2024) & (K Units)
Figure 21. Global Tumor Immunotherapy Drugs Sales Market Share by Application (2023)
Figure 22. Global Tumor Immunotherapy Drugs Revenue Market Share by Application in 2023
Figure 23. Tumor Immunotherapy Drugs Sales Market by Company in 2023 (K Units)
Figure 24. Global Tumor Immunotherapy Drugs Sales Market Share by Company in 2023
Figure 25. Tumor Immunotherapy Drugs Revenue Market by Company in 2023 ($ Million)
Figure 26. Global Tumor Immunotherapy Drugs Revenue Market Share by Company in 2023
Figure 27. Global Tumor Immunotherapy Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Tumor Immunotherapy Drugs Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Tumor Immunotherapy Drugs Sales 2019-2024 (K Units)
Figure 30. Americas Tumor Immunotherapy Drugs Revenue 2019-2024 ($ Millions)
Figure 31. APAC Tumor Immunotherapy Drugs Sales 2019-2024 (K Units)
Figure 32. APAC Tumor Immunotherapy Drugs Revenue 2019-2024 ($ Millions)
Figure 33. Europe Tumor Immunotherapy Drugs Sales 2019-2024 (K Units)
Figure 34. Europe Tumor Immunotherapy Drugs Revenue 2019-2024 ($ Millions)
Figure 35. Middle East & Africa Tumor Immunotherapy Drugs Sales 2019-2024 (K Units)
Figure 36. Middle East & Africa Tumor Immunotherapy Drugs Revenue 2019-2024 ($ Millions)
Figure 37. Americas Tumor Immunotherapy Drugs Sales Market Share by Country in 2023
Figure 38. Americas Tumor Immunotherapy Drugs Revenue Market Share by Country in 2023
Figure 39. Americas Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
Figure 40. Americas Tumor Immunotherapy Drugs Sales Market Share by Application (2019-2024)
Figure 41. United States Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 42. Canada Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 43. Mexico Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 44. Brazil Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 45. APAC Tumor Immunotherapy Drugs Sales Market Share by Region in 2023
Figure 46. APAC Tumor Immunotherapy Drugs Revenue Market Share by Regions in 2023
Figure 47. APAC Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
Figure 48. APAC Tumor Immunotherapy Drugs Sales Market Share by Application (2019-2024)
Figure 49. China Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 50. Japan Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 51. South Korea Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 52. Southeast Asia Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 53. India Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 54. Australia Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 55. China Taiwan Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 56. Europe Tumor Immunotherapy Drugs Sales Market Share by Country in 2023
Figure 57. Europe Tumor Immunotherapy Drugs Revenue Market Share by Country in 2023
Figure 58. Europe Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
Figure 59. Europe Tumor Immunotherapy Drugs Sales Market Share by Application (2019-2024)
Figure 60. Germany Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 61. France Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 62. UK Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 63. Italy Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 64. Russia Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 65. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Country in 2023
Figure 66. Middle East & Africa Tumor Immunotherapy Drugs Revenue Market Share by Country in 2023
Figure 67. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Application (2019-2024)
Figure 69. Egypt Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 70. South Africa Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 71. Israel Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 72. Turkey Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 73. GCC Country Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Tumor Immunotherapy Drugs in 2023
Figure 75. Manufacturing Process Analysis of Tumor Immunotherapy Drugs
Figure 76. Industry Chain Structure of Tumor Immunotherapy Drugs
Figure 77. Channels of Distribution
Figure 78. Global Tumor Immunotherapy Drugs Sales Market Forecast by Region (2025-2030)
Figure 79. Global Tumor Immunotherapy Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Tumor Immunotherapy Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Tumor Immunotherapy Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Tumor Immunotherapy Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 83. Global Tumor Immunotherapy Drugs Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Tumor Immunotherapy Drugs
Figure 2. Tumor Immunotherapy Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Tumor Immunotherapy Drugs Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Tumor Immunotherapy Drugs Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Tumor Immunotherapy Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Immune Checkpoint Inhibitors
Figure 10. Product Picture of Tumor Vaccine
Figure 11. Product Picture of Adoptive Immunotherapy
Figure 12. Product Picture of Non-specific Immunomodulator
Figure 13. Global Tumor Immunotherapy Drugs Sales Market Share by Type in 2023
Figure 14. Global Tumor Immunotherapy Drugs Revenue Market Share by Type (2019-2024)
Figure 15. Tumor Immunotherapy Drugs Consumed in Hospital
Figure 16. Global Tumor Immunotherapy Drugs Market: Hospital (2019-2024) & (K Units)
Figure 17. Tumor Immunotherapy Drugs Consumed in Clinic
Figure 18. Global Tumor Immunotherapy Drugs Market: Clinic (2019-2024) & (K Units)
Figure 19. Tumor Immunotherapy Drugs Consumed in Other
Figure 20. Global Tumor Immunotherapy Drugs Market: Other (2019-2024) & (K Units)
Figure 21. Global Tumor Immunotherapy Drugs Sales Market Share by Application (2023)
Figure 22. Global Tumor Immunotherapy Drugs Revenue Market Share by Application in 2023
Figure 23. Tumor Immunotherapy Drugs Sales Market by Company in 2023 (K Units)
Figure 24. Global Tumor Immunotherapy Drugs Sales Market Share by Company in 2023
Figure 25. Tumor Immunotherapy Drugs Revenue Market by Company in 2023 ($ Million)
Figure 26. Global Tumor Immunotherapy Drugs Revenue Market Share by Company in 2023
Figure 27. Global Tumor Immunotherapy Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Tumor Immunotherapy Drugs Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Tumor Immunotherapy Drugs Sales 2019-2024 (K Units)
Figure 30. Americas Tumor Immunotherapy Drugs Revenue 2019-2024 ($ Millions)
Figure 31. APAC Tumor Immunotherapy Drugs Sales 2019-2024 (K Units)
Figure 32. APAC Tumor Immunotherapy Drugs Revenue 2019-2024 ($ Millions)
Figure 33. Europe Tumor Immunotherapy Drugs Sales 2019-2024 (K Units)
Figure 34. Europe Tumor Immunotherapy Drugs Revenue 2019-2024 ($ Millions)
Figure 35. Middle East & Africa Tumor Immunotherapy Drugs Sales 2019-2024 (K Units)
Figure 36. Middle East & Africa Tumor Immunotherapy Drugs Revenue 2019-2024 ($ Millions)
Figure 37. Americas Tumor Immunotherapy Drugs Sales Market Share by Country in 2023
Figure 38. Americas Tumor Immunotherapy Drugs Revenue Market Share by Country in 2023
Figure 39. Americas Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
Figure 40. Americas Tumor Immunotherapy Drugs Sales Market Share by Application (2019-2024)
Figure 41. United States Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 42. Canada Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 43. Mexico Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 44. Brazil Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 45. APAC Tumor Immunotherapy Drugs Sales Market Share by Region in 2023
Figure 46. APAC Tumor Immunotherapy Drugs Revenue Market Share by Regions in 2023
Figure 47. APAC Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
Figure 48. APAC Tumor Immunotherapy Drugs Sales Market Share by Application (2019-2024)
Figure 49. China Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 50. Japan Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 51. South Korea Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 52. Southeast Asia Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 53. India Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 54. Australia Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 55. China Taiwan Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 56. Europe Tumor Immunotherapy Drugs Sales Market Share by Country in 2023
Figure 57. Europe Tumor Immunotherapy Drugs Revenue Market Share by Country in 2023
Figure 58. Europe Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
Figure 59. Europe Tumor Immunotherapy Drugs Sales Market Share by Application (2019-2024)
Figure 60. Germany Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 61. France Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 62. UK Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 63. Italy Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 64. Russia Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 65. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Country in 2023
Figure 66. Middle East & Africa Tumor Immunotherapy Drugs Revenue Market Share by Country in 2023
Figure 67. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Tumor Immunotherapy Drugs Sales Market Share by Application (2019-2024)
Figure 69. Egypt Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 70. South Africa Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 71. Israel Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 72. Turkey Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 73. GCC Country Tumor Immunotherapy Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Tumor Immunotherapy Drugs in 2023
Figure 75. Manufacturing Process Analysis of Tumor Immunotherapy Drugs
Figure 76. Industry Chain Structure of Tumor Immunotherapy Drugs
Figure 77. Channels of Distribution
Figure 78. Global Tumor Immunotherapy Drugs Sales Market Forecast by Region (2025-2030)
Figure 79. Global Tumor Immunotherapy Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Tumor Immunotherapy Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Tumor Immunotherapy Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Tumor Immunotherapy Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 83. Global Tumor Immunotherapy Drugs Revenue Market Share Forecast by Application (2025-2030)
